Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Interventional Cardiology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Interventional Cardiology
    Targeted Leads in Cardiac Resynchronisation Therapy Improve Outcomes Substantially: Presented at CCC - (DGDispatch)
    Combining Complex Fractionated Electrograms With Pulmonary Vein Isolation Best of 3 Strategies for Treating Atrial Fibrillation: Presented at CCC - (DGDispatch)
    Radial Approach to PCI Associated With Less Bleeding Relative to the Femoral Approach: Presented at CCC - (DGDispatch)
    Study Disputes Link Between Coronary Artery Bypass Grafting and Cognitive Decline: Presented at ANA - (DGDispatch)
    Defibrillator Implantation Early after Myocardial Infarction - (N Engl J Med)

    News archive

     Recent webcasts/CME - Interventional Cardiology
      PreAnesthetic Assessment of the Patient With Cardiomyopathy
      Pulmonary Hypertension: Advances in Pulmonary Hypertension
      New Clinical Evidence for Home Monitoring: Towards Safe, Need-based Patient Follow-up and Beyond
      Simplification of AF: Integration of 3D Imaging, Mapping, and Ablation
      Emerging Trends in the Management of Arrhythmias and Pump Failure in Patients with Advanced HF

      Webcasts/CME archive

       Recent cases - Interventional Cardiology
        Myocardial Ischemia with Left Ventricular Outflow Obstruction
        Successful Non Contrast Percutaneous Coronary Intervention for Patient with Unstable Angina and Prior Anaphylactic Reaction to Iodinated Contrast Medium
        Quantitative Assessment of Dyssynchrony Using ECG-Gated SPECT Myocardial Perfusion Imaging Prior to and Following Cardiac Resynchronization Therapy
        Automatic Implantable Cardioverter Defibrillator Pocket Infection Due to Providencia rettgeri: A Case Report
        Pacemaker Induced Superior Vena Cava Syndrome: A Case Report

        Cases archive
          




        my personal edition > interventional cardiology > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Similar Early Outcomes With Eptifibatide and Abciximab Before Percutaneous Coronary Intervention: Presented at SCAI

        By Crystal Phend

        CHICAGO, I.L. -- May 15, 2006 -- The glycoprotein IIb/IIIa inhibitors abciximab and eptifibatide appear to be equally effective in improving in-hospital outcomes when given before a percutaneous coronary intervention (PCI), according to a study presented here at the Society for Cardiovascular Angiography and Interventions annual meeting (SCAI).

        Preliminary trials have shown upstream use of abciximab to improve mortality and early restoration of blood flow through a blocked artery. However, "the data on eptifibatide in primary PCI is far more limited than for abciximab," said lead author Rachid Elkoustaf, MD, MPH, senior cardiology fellow, Hartford Hospital, Hartford, Connecticut, in a presentation May 11th.

        The researchers analyzed outcomes for 308 consecutive patients who presented with ST-segment elevation myocardial infarction (MI) and were initially treated with abciximab (176 patients) or eptifibatide (132 patients) and then referred to a tertiary care center to receive PCI.

        Risk factors and cardiovascular intervention history were similar between groups as was the severity of disease found on diagnostic catheterization. Patients who received eptifibatide were more likely to receive adjunctive clopidogrel (12% vs. 0.6%) and low molecular weight heparin (8% versus 2%), but were less likely to get thrombolytic agents (61% versus 85%) than those in the abciximab group.

        PCI procedure results were not significantly different between the treatment arms. While 55.7% of abciximab-treated patients and 54.2% of eptifibatide-treated patients had complete perfusion (Thrombolysis in Myocardial Infarction 3 flow) initially, that improved to 93.2% and 97.7%, respectively, after the procedure. Stents were placed during 93.2% of procedures in the abciximab group and 88.6% of the eptifibatide group.

        Major adverse outcomes reported were all similar between abciximab and eptifibatide groups, including death (3.41% vs. 5.3%), recurrent MI (0% vs. 0.8%), total major adverse cardiovascular events (8% vs. 12.1%), stroke (0.6% vs. 0.08%) and repeat PCI (1.1% vs. 2.3%).

        The bleeding risk also appeared to be similar between abciximab and eptifibatide, with minor bleeds occurring in 10.2% and 12.9% and major bleeds 7.4% and 9.8%, respectively.

        The researchers concluded that upstream abciximab and eptifibatide result in comparable early outcomes.


        [Presentation title: The Impact of Pre-Treatment With Eptifibatide Compared With Abciximab On in-Hospital Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Treated With Facilitated Percutaneous Coronary Intervention. Abstract A-49]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send